Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Subscribe To Our Newsletter & Stay Updated
